BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

956 related articles for article (PubMed ID: 16751782)

  • 21. Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia.
    Myoken Y; Sugata T; Kyo T; Fujihara M; Mikami Y
    J Periodontol; 2002 Jan; 73(1):33-8. PubMed ID: 11846198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
    Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
    Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevention of fungal infections in children and adolescents with cancer].
    Groll AH; Ritter J; Müller FM
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A50-68. PubMed ID: 11577364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.
    Kontoyiannis DP; Marr KA; Park BJ; Alexander BD; Anaissie EJ; Walsh TJ; Ito J; Andes DR; Baddley JW; Brown JM; Brumble LM; Freifeld AG; Hadley S; Herwaldt LA; Kauffman CA; Knapp K; Lyon GM; Morrison VA; Papanicolaou G; Patterson TF; Perl TM; Schuster MG; Walker R; Wannemuehler KA; Wingard JR; Chiller TM; Pappas PG
    Clin Infect Dis; 2010 Apr; 50(8):1091-100. PubMed ID: 20218877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy.
    Grigull L; Kuehlke O; Beilken A; Sander A; Linderkamp C; Schmid H; Seidemann K; Sykora KW; Schuster FR; Welte K
    Pediatr Transplant; 2007 May; 11(3):261-6. PubMed ID: 17430480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
    van Burik JA; Ratanatharathorn V; Stepan DE; Miller CB; Lipton JH; Vesole DH; Bunin N; Wall DA; Hiemenz JW; Satoi Y; Lee JM; Walsh TJ;
    Clin Infect Dis; 2004 Nov; 39(10):1407-16. PubMed ID: 15546073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.
    Hamza NS; Ghannoum MA; Lazarus HM
    Bone Marrow Transplant; 2004 Sep; 34(5):377-89. PubMed ID: 15247928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
    Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
    Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol.
    Castagnola E; Bucci B; Montinaro E; Viscoli C
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():97-106. PubMed ID: 8932808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
    Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
    Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients.
    Post MJ; Lass-Floerl C; Gastl G; Nachbaur D
    Transpl Infect Dis; 2007 Sep; 9(3):189-95. PubMed ID: 17511828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation.
    Camps IR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S119-23. PubMed ID: 19013335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.
    Hovi L; Saarinen-Pihkala UM; Vettenranta K; Saxen H
    Bone Marrow Transplant; 2000 Nov; 26(9):999-1004. PubMed ID: 11100280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT.
    Blennow O; Remberger M; Klingspor L; Omazic B; Fransson K; Ljungman P; Mattsson J; Ringdén O
    Bone Marrow Transplant; 2010 Dec; 45(12):1710-8. PubMed ID: 20190840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
    Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
    Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.